KBI Biopharma is expanding its development and manufacturing capabilities through the acquisition of a microbial research and manufacturing facility operated by Merck & Co. in Colorado.
Financial terms were not disclosed.
The deal was announced early Tuesday but KBI assumed control of it on May 1.
The facility is located in Boulder, Col.
KBI will continue to provide services and development to Merck as part of the deal.
“We are very pleased to continue to advance our partnership with Merck, and to welcome this very highly regarded team of scientists in Boulder to the KBI team,” said Joe McMahon, KBI’s President and CEO. “KBI will now offer expanded microbial development and manufacturing services up to 1500L scale, as well as continuing to offer our current full range of process development, analytical and formulation development and mammalian manufacturing services up to 2000L.”
KBI also works with Merck through its two operations in North Carolina.
The company has worked with clients to develop more than 220 molecules across 55 potential health applications.
